GlassScriptPhysician profile
Amarbir Bhullar
NPI 1790199453
$33,414.35
in general payments reported to CMS, 2019-2025
33 companies · $2,709 in 2025
The $2,709 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $9,096 · 2021: $7,260 · 2022: $6,889 · 2023: $881 · 2024: $6,270 · 2025: $2,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,880 · Travel and Lodging: $2,963 · Education: $16.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,879.62 |
| Travel and Lodging | $2,963.34 |
| Education | $16.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,190.10 | 2020-2025 | General - Therapies, Watchman Flx, Accolade Sr |
| Biotronik INC. | $5,409.34 | 2021-2025 | Biomonitor, Amvia Edge, Acticor 7 Vr-T Dx |
| Medtronic Vascular, INC. | $5,067.59 | 2019-2020 | |
| Abbott Laboratories | $4,378.97 | 2020-2025 | Ensite, Perclose Prostyle, Aveir |
| Medtronic, INC. | $3,966.49 | 2021-2025 | Micra, Corevalve Evolut R, Cobalt Dr Mri Surescan |
| Amgen INC. | $1,481.71 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $1,236.31 | 2021-2024 | (9520) Igt Devices Undivided, (Bs2) Lm Undivided, (Am5) Lead Management |
| Biosense Webster, INC. | $509.32 | 2022-2025 | Qdot Micro Catheter, Nuvision Ice Catheter |
| Cardiva Medical, INC. | $493.09 | 2024-2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f, Savvywire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.80 | 2022-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $334.06 | 2022-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $290.58 | 2022-2025 | Verquvo, Capvaxive |
| Actelion Pharmaceuticals US, INC. | $287.94 | 2022-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $192.10 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $187.73 | 2024 | Inpefa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $181.82 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $139.48 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $138.62 | 2025 | Amvuttra |
| United Therapeutics Corporation | $116.24 | 2019 | |
| Pfizer INC. | $85.97 | 2023-2025 | |
| Chiesi USA, INC. | $54.84 | 2020-2023 | Kengreal |
| Abiomed | $51.36 | 2025 | |
| Cordis US Corp. | $46.08 | 2024 | Mynx Venous Vcd |
| Glaxosmithkline, LLC. | $44.26 | 2025 | Shingrix |
| Astrazeneca Pharmaceuticals LP | $40.43 | 2023 | Brilinta |
| Edwards Lifesciences Corporation | $33.17 | 2023 | Sapien 3 Ultra Resilia |
| Cvrx, INC. | $23.13 | 2023 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $19.32 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $17.92 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $17.59 | 2023 | Evkeeza |
| Daiichi Sankyo INC. | $17.34 | 2024 | Injectafer |
| Baylis Medical Company INC | $13.67 | 2021 | |
| Convatec INC. | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amarbir Bhullar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.